Legato Capital Management LLC Makes New $861,000 Investment in Gilead Sciences, Inc. $GILD

Legato Capital Management LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 7,016 shares of the biopharmaceutical company’s stock, valued at approximately $861,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Massachusetts Financial Services Co. MA lifted its position in shares of Gilead Sciences by 3,763.8% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock worth $518,368,000 after purchasing an additional 4,113,999 shares during the period. Vanguard Group Inc. lifted its position in shares of Gilead Sciences by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after purchasing an additional 2,113,692 shares during the period. First Trust Advisors LP lifted its position in shares of Gilead Sciences by 154.3% in the 3rd quarter. First Trust Advisors LP now owns 3,089,283 shares of the biopharmaceutical company’s stock worth $342,910,000 after purchasing an additional 1,874,508 shares during the period. Invesco Ltd. lifted its position in shares of Gilead Sciences by 12.0% in the 3rd quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock worth $1,680,505,000 after purchasing an additional 1,618,453 shares during the period. Finally, Danske Bank A S acquired a new position in shares of Gilead Sciences in the 3rd quarter worth approximately $133,049,000. 83.67% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on GILD shares. Truist Financial restated a “buy” rating and issued a $157.00 price target (up from $155.00) on shares of Gilead Sciences in a research report on Friday, May 8th. Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price target on the stock in a research report on Wednesday, May 20th. Barclays started coverage on shares of Gilead Sciences in a research report on Friday, February 20th. They issued an “equal weight” rating and a $155.00 price target on the stock. Citigroup boosted their target price on shares of Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Finally, Wall Street Zen downgraded shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Twenty-five research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $156.93.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $132.27, for a total transaction of $396,810.00. Following the completion of the transaction, the chief financial officer owned 173,191 shares in the company, valued at approximately $22,907,973.57. This represents a 1.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the transaction, the chief executive officer owned 632,567 shares of the company’s stock, valued at approximately $81,702,353.72. The trade was a 1.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 63,000 shares of company stock worth $8,523,570. 0.30% of the stock is owned by company insiders.

Gilead Sciences Price Performance

GILD opened at $134.36 on Tuesday. The firm has a market cap of $166.82 billion, a P/E ratio of 18.31 and a beta of 0.31. The firm has a 50-day moving average of $136.05 and a 200 day moving average of $133.81. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. Gilead Sciences, Inc. has a fifty-two week low of $104.46 and a fifty-two week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.12. The company had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, research analysts expect that Gilead Sciences, Inc. will post -0.79 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be given a dividend of $0.82 per share. The ex-dividend date is Monday, June 15th. This represents a $3.28 annualized dividend and a yield of 2.4%. Gilead Sciences’s dividend payout ratio is presently 44.69%.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead completed its $3.15 billion acquisition of Tubulis GmbH, adding a new antibody-drug conjugate platform that should strengthen its oncology pipeline and broaden growth opportunities. Gilead Sciences (GILD) Acquires Tubulis for $3.15B to Expand Oncology Portfolio
• Positive Sentiment: Gilead received an FDA approval for Hepcludex, the first U.S. treatment for chronic hepatitis delta, while Europe’s CHMP backed Trodelvy for triple-negative breast cancer, reinforcing the company’s near-term commercial and pipeline momentum. GILD Scores FDA Win for HDV Drug, CHMP Backs Trodelvy
• Positive Sentiment: Maxim upgraded Gilead Sciences to Buy, adding to the view that the shares remain attractive at current levels and are supported by dividend income and a solid franchise. Maxim Upgrades Gilead Sciences (GILD) to ‘Buy’
• Positive Sentiment: Brokerage coverage remains supportive overall, with Gilead carrying an average “Moderate Buy” rating, which can help underpin investor sentiment. Gilead Sciences, Inc. (NASDAQ:GILD) Receives Average Rating of “Moderate Buy” from Brokerages
• Neutral Sentiment: Articles discussing stocks trading below estimated fair value are broad market pieces and do not provide a specific company-specific catalyst for Gilead. Three Stocks That May Be Trading Below Their Estimated Value In May 2026
• Neutral Sentiment: Another “top stocks trading below fair value” market roundup is similarly general and not a direct catalyst for GILD. May 2026’s Top Stocks That Could Be Trading Below Estimated Fair Value

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.